No Data
Candel Therapeutics' CAN-2409: Strategic Partnerships and Promising Clinical Data Drive Buy Rating
Insider Sale: Chief Medical Officer of $CADL Sells 45,316 Shares
Small Cap Wrap: Santacruz Silver, GoviEx Uranium, Candel Therapeutics...
Candel Therapeutics Partners With IDEA Pharma on Commercialization of Lead Asset CAN-2409 | NASDAQ:CADL
Candel Therapeutics And IDEA Pharma Announce Commercial Partnership, IDEA To Provide Commercial Input Throughout Candel's Development And Commercialization Process For CAN-2409
Express News | Candel Therapeutics and Idea Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for Can-2409
72991267 : What is the company worth? It is $400 Million, or $4 Billion. Based on Prostate cancer reduction alone it should be $1.5 Billion. It will take time, but the Market Cap should increase as more big investors get a bigger share of the pie.